Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.  

The webcast will be available via this link.  

An archived version of the webcast will be available for at least one year in the Investors section of the Company's website at www.acumenpharm.com.

About Acumen Pharmaceuticals, Inc. 

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its lead investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme's proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery™ (EBD®) therapy for Alzheimer's disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
ICR Healthcare
AcumenPR@icrhealthcare.com 


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ABOS
The Conversation (0)
Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases

Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases

Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesityEvotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomicsLille University... Keep Reading...

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024 Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 Cash, cash equivalents and marketable... Keep Reading...

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C.... Keep Reading...

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank... Keep Reading...

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer's Disease

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug... Keep Reading...
Chalice Modular Plant MOU

Chalice Modular Plant MOU

Corazon Mining (CZN:AU) has announced Chalice Modular Plant MOUDownload the PDF here. Keep Reading...
Bahia Metals Announces C$1.2 Million Private Placement with Expected Full Participation by Strategic Investor

Bahia Metals Announces C$1.2 Million Private Placement with Expected Full Participation by Strategic Investor

Bahia Metals Corp. (CSE: BMT) ("Bahia" or the "Company") is pleased to announce a non-brokered private placement of up to 6,000,000 units of the Company (the "Units") at a price of C$0.20 per Unit for aggregate gross proceeds of up to C$1,200,000 (the "Offering"). CEI Energética ("CEI"), a... Keep Reading...
Why Gold, Silver and Critical Minerals Are Converging into One Compelling Investment Opportunity

Why Gold, Silver and Critical Minerals Are Converging into One Compelling Investment Opportunity

MiningNewsWire Editorial Coverage: Renewed safe-haven demand for gold and silver is building as U.S. debt climbs past 100% of GDP and central banks keep accumulating gold. At the same time, the federal 2025 List of Critical Minerals now covers silver, copper, lead and zinc, turning familiar... Keep Reading...
Transition Metals Advances Saturday Night with Deep-Penetrating Geophysics, Reports 2026 Summer Exploration Results

Transition Metals Advances Saturday Night with Deep-Penetrating Geophysics, Reports 2026 Summer Exploration Results

Key Highlights:Saturday Night: Coincident SPARTAN MT and gravity surveys underway, which look to improve subsurface geological interpretations and refine prospective drill targets.Gowganda: Mechanical stripping confirms structural and lithological trends associated with mineralization.Cryderman:... Keep Reading...
Metalsource Mining Moves to Unlock Byrd-Pilot Value Through Potential Spinout or Strategic Transaction

Metalsource Mining Moves to Unlock Byrd-Pilot Value Through Potential Spinout or Strategic Transaction

Strategic initiative aims to unlock shareholder value through Byrd-Pilot's copper-gold porphyry exploration potential while accelerating aggressive expansion drilling and larger stepouts at Silver Hill.Metalsource Mining Inc. (CSE: MSM) (OTCQB: MSMMF) (FSE: E9Z) ("Metalsource" or the "Company")... Keep Reading...
Questcorp Mining and Riverside Resources Commence Phase 2B Drilling at Luis Hill, La Union Project, Sonora, Mexico

Questcorp Mining and Riverside Resources Commence Phase 2B Drilling at Luis Hill, La Union Project, Sonora, Mexico

Questcorp Mining Inc. (CSE: QQQ) (OTCQB: QQCMF) (FSE: D910) (the "Company" or "Questcorp") and its joint venture partner and operator Riverside Resources Inc. ("Riverside") are pleased to announce the commencement of Phase 2B reverse circulation ("RC") drilling at the Luis Hill target at the La... Keep Reading...

Interactive Chart

Latest Press Releases

Related News